Information Provided By:
Fly News Breaks for November 18, 2019
Nov 18, 2019 | 05:33 EDT
Piper Jaffray analyst Matt O'Brien took over coverage of DexCom and reiterates an Overweight rating on the shares with a price target of $230, up from $200. The company has seen an inflection in growth driven by its product that does not require the patient to finger stick anymore, says the analyst.